Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi (VITAL)
Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi
Sponsor: Astellas Pharma Inc
Listed as NCT00634049, this PHASE3 trial focuses on Aspergillosis and Invasive Fungal Infections and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 12 times since 2008, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
12 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE3
-
Dec 2025 — Mar 2026 [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Jan 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jan 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Apr 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
- Basilea Pharmaceutica International Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Ahmedabad, India , Albany, United States , Alexandria, Egypt , Atlanta, United States , Aurora, United States , Beech Grove, United States , Beirut, Lebanon , Belo Horizonte, Brazil , Berlin, Germany and 71 more locations